Biotechnology company developing allogeneic, off-the-shelf virus-specific T cell therapies for viral diseases.
Allovir, Inc., based in Waltham, Massachusetts, is a pioneering clinical-stage cell therapy company dedicated to advancing allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for the prevention and treatment of severe viral-associated diseases. The company's flagship product, posoleucel, represents a breakthrough in immunotherapy, offering a standardized, scalable treatment option for viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
In addition to posoleucel, Allovir is actively developing a robust pipeline of preclinical and clinical-stage product candidates. ALVR106 targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus, addressing critical respiratory infections. ALVR109 is focused on combating SARS-CoV-2 and COVID-19, aiming to provide effective therapeutic solutions against the ongoing global pandemic.
Further expanding its therapeutic reach, Allovir is advancing ALVR107 for the treatment of heppatitis B virus infections and ALVR108 for additional viral indications. These efforts underscore Allovir's commitment to leveraging cutting-edge cell therapy technologies to address unmet medical needs across a spectrum of viral diseases.
Founded in 2013 as ViraCyte, Inc. and rebranded as Allovir, Inc. in May 2019, the company has rapidly emerged as a leader in the field of viral immunotherapy. With a strong foundation in scientific innovation and strategic partnerships, Allovir continues to push the boundaries of treatment possibilities, aiming to transform the landscape of viral disease management through its pioneering approach in cell-based therapies.